Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23037418 | 1.00 | PRKCA (0.53) | PRKCAMAPK1MAPTTSHRPRKCD | |
| SCHEMBL1426847 | 0.84 | PRKCA (0.44) | PRKCAMAPK1MAPTPRKCD | |
| SCHEMBL17964189 | 0.84 | MAPK1 (0.44) | PRKCAMAPK1MAPTTSHRHSD17B10 | |
| SCHEMBL685935 | 0.83 | PRKCA (0.55) | PRKCATSHRPRKCDPOLBGAA | |
| SCHEMBL9463647 | 0.83 | PRKCA (0.55) | PRKCAPRKCDELANEPOLBGAA | |
| SCHEMBL13168170 | 0.83 | PRKCA (0.55) | PRKCAMAPK1MAPTTSHRPRKCD | |
| SCHEMBL4203122 | 0.82 | MAPT (0.46) | PRKCAMAPK1MAPTHSD17B10GAA | |
| SCHEMBL9152175 | 0.82 | PRKCA (0.50) | PRKCAMAPK1PRKCDELANEPOLB | |
| SCHEMBL4029951 | 0.82 | MAPK1 (0.43) | PRKCAMAPK1MAPTTSHRHSD17B10 | |
| SCHEMBL18388530 | 0.81 | PRKCA (0.53) | PRKCAMAPK1TSHRPRKCDELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129258-B2 | Diaryl macrocyclic compound and pharmaceutical composition, and use thereof | PRIMEGENE (BEIJING) CO., LTD (CN) | 2024-10-29 | — | — | US | disclosed |
| EP-3786167-B1 | DIARYL MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | PRIMEGENE BEIJING CO LTD (CN) | 2024-08-21 | — | — | EP | disclosed |
| US-20220162218-A1 | DIARYL MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| EP-3786167-A1 | DIARYL MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | Primegene (Beijing) Co., Ltd. (CN) | 2021-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162218-A1 | DIARYL MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | SRC, CYP11B1, LCK | PRKCA 956/4885MAPK1 105/4885MAPT 718/4885 |
| US-12129258-B2 | Diaryl macrocyclic compound and pharmaceutical composition, and use thereof | SRC, CYP11B1, LCK | PRKCA 992/4885MAPK1 110/4885MAPT 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.